We could not find any results for:
Make sure your spelling is correct or try broadening your search.
IRVINE, California, October 29 /PRNewswire-FirstCall/ -- IsoTis, Inc. (NASDAQ:ISOT) ("IsoTis"), an orthobiologics company, today announced that, at the special meeting of stockholders...
IRVINE, California, October 29 /PRNewswire-FirstCall/ -- IsoTis, Inc. (NASDAQ:ISOT) ("IsoTis"), an orthobiologics company, today announced that, at the special meeting of stockholders...
Less Than 40,000 Additional "FOR" Votes Required for Integra Merger IRVINE, California, October 26 /PRNewswire-FirstCall/ -- IsoTis, Inc. (NASDAQ:ISOT) ("IsoTis"), an orthobiologics company...
Less Than 100,000 Additional "FOR" Votes Required for Integra Merger IRVINE, California, October 26 /PRNewswire-FirstCall/ -- IsoTis, Inc. (NASDAQ:ISOT) ("IsoTis"), an orthobiologics company...
Less Than 350,000 Additional Votes "FOR" Required for Integra Merger IRVINE, California, October 24 /PRNewswire-FirstCall/ -- IsoTis, Inc. (NASDAQ:ISOT) ("IsoTis"), an orthobiologics company...
Conference Calls to Answer Questions About Stockholder Meeting October 23 IRVINE, California, October 16 /PRNewswire-FirstCall/ -- IsoTis, Inc. (NASDAQ:ISOT) ("IsoTis"), an orthobiologics...
IRVINE, California, October 16 /PRNewswire-FirstCall/ -- - Conference Calls to Answer Questions About Stockholder Meeting October 23 IsoTis, Inc. (NASDAQ:ISOT) ("IsoTis"), an orthobiologics...
IRVINE, California, October 11 /PRNewswire-FirstCall/ -- IsoTis, Inc. (NASDAQ:ISOT) ("IsoTis"), an orthobiologics company, today announced that it has adjourned the special meeting of...
Leading Proxy Advisor Recommends Shareholders Support Merger IRVINE, California, September 19 /PRNewswire-FirstCall/ -- IsoTis, Inc. (NASDAQ:ISOT) ("IsoTis"), an orthobiologics company, today...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions